Thomas Kias
Internal Medicine · Athens, GANPI 1609848373
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Gilead at 27.5% of the total. Reporting peaked in 2019 at $516 and has fallen 64.3% since, to $184 in 2025.
Across 72 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$336
- AstraZeneca$130
- Novo Nordisk$105
- Amgen$79
- Amarin Pharma, Inc.$74
- Astellas Pharma US Inc$68
- plus $428 from 16 others
What the payments were for
- Food & beverage$1,220100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 14 | $336 |
| AstraZeneca | 8 | $130 |
| Novo Nordisk | 7 | $105 |
| Amgen | 5 | $79 |
| Amarin Pharma, Inc. | 5 | $74 |
| Astellas Pharma US Inc | 4 | $68 |
| Pfizer | 4 | $61 |
| Lilly USA, LLC | 4 | $59 |
| Dexcom, Inc. | 3 | $50 |
| Merck | 3 | $39 |
| Currax Pharmaceuticals LLC | 2 | $33 |
| Viiv Healthcare Company | 2 | $31 |
| GSK | 2 | $30 |
| Boston Scientific | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| AbbVie | 1 | $15 |
| Nalpropion Pharmaceuticals LLC | 1 | $14 |
| Medtronic | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Boehringer Ingelheim | 1 | $12 |
How this compares
$1,220 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 45 | $170,272 |
| DovatoDolutegravir Sodium/Lamivudine | 17 | $49,311 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $3,905 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $382 |
| Bupropion XlBupropion Hcl | 15 | $152 |
| Trazodone Hcl | 13 | $63 |
| Lisinopril | 13 | $11 |
| Citalopram HbrCitalopram Hydrobromide | 11 | $4 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $336 | $170,27245 claims |
| Viiv Healthcare CompanyDovato | $31 | $49,31117 claims |
| AstraZenecaSymbicort | $130 | $3,90517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Athens
- Asif QadriAthens$18K
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.